Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Elan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Elan

Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan

4Q Revenues: $269.8 million (+24%)       

4Q Earnings: $169.5 million (loss of $83.5 million in 4Q07)
   
FY Revenues: $1.0 billion (+32%)

FY Loss: $71.0 million (loss of $405 million FY08)

Comments: Revenue from the Biopharmaceuticals business was up 29% in the quarter and 51% for the year, driven by a strong performance from Tysabri, which offset reduced sales of Maxipime due to generic competition. For the quarter and full year, recorded Tysabri sales were $152.2 million (+68%) and $557.1 million (+140%), respectively. Earnings in the quarter include a $236.6 million tax benefit. R&D expenses for the year increased 26% to $328.7 million, primarily related to the clinical advancement of the company’s Alzheimer’s disease programs. The decrease in the net loss for the year resulted from improved operating performance, a net deferred tax asset of $236.6 million, and reduced charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters